Eisai (ESAIY) and Biogen (BIIB) announced an update on the ongoing regulatory review of the Marketing Authorization Application, MAA, for ...

Eisai will begin communicating with PCPs in ... partnership opportunities and in-house manufacturing of its major products. The company’s three pillars for medium to long-term growth lay in ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. Weeks after Eisai quietly made its choice, its liquid biopsy partner has revealed Bliss ...

Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion ...

Eisai shares fell sharply after its Alzheimer’s drug failed to secure marketing approval in the European Union. Shares were recently 12% lower at 5,852 yen, or about $38.06, Monday morning after ...

February 28, 2025 EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for ...

It has also partnered with Tokyo-based Lifenet Insurance Co to develop a series of insurance products specifically for people with dementia and other ageing-related diseases. "Eisai believes that ...

Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) today provided an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab – trade name Leqembi - as a treatment for ...

STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi.

Eisai & Biogen update on regulatory review of MAA for lecanemab for early Alzheimer’s disease by the European Commission: Tokyo Wednesday, April 2, 2025, 16:00 Hrs [IST] Eisai C ...

A partnership between Eisai and Lifenet that aims to improve ... The alliance, first formed in 2022, envisages a series of insurance products specifically for people in Japan with dementia and ...

Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab ...